The treatment of HER2-positive breast cancer is being revolutionized by ADCs; they are efficiently used to deliver the cytotoxic agent by using monoclonal antibodies with reduced off-side toxicities, and examples include trastuzumab deruxtecan, ARX788, and ZW49. This evidence concerns the gene ERBB2 and breast cancer.